SCHEMBL19729201

SCHEMBL19729201

Cc1ccc(Br)c(C(=O)O)c1N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.38
KMT2A Q03164 1/20 0.38
GLA P06280 1/20 0.37
POLB P06746 1/20 0.35
NOTUM Q6P988 1/20 0.35
TDP1 Q9NUW8 2/20 0.34
MAPT P10636 1/20 0.34
CYP3A4 P08684 1/20 0.34
ACHE P22303 1/20 0.34
ALKBH5 Q6P6C2 2/20 0.33
DHODH Q02127 1/20 0.33
PDE10A Q9Y233 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ALDH1A1 P00352 3/20 0.33
HSD17B10 Q99714 1/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30762392 0.84 KDM4E (0.38) KDM4EKMT2AGLAPOLBNOTUM
SCHEMBL31030163 0.83 KDM4E (0.42) KDM4EKMT2APOLBNOTUMTDP1
SCHEMBL15713616 0.83 KDM4E (0.42) KDM4EKMT2AGLAPOLBTDP1
SCHEMBL6620704 0.83 KDM4E (0.42) KDM4EKMT2APOLBNOTUMTDP1
SCHEMBL11396178 0.79 CD44 (0.43) KDM4EKMT2AGLAPOLBNOTUM
SCHEMBL5693090 0.79 NOTUM (0.38) NOTUMTDP1CYP3A4ACHEALKBH5
SCHEMBL28950924 0.78 KDM4E (0.52) KDM4EKMT2ANOTUMTDP1MAPT
SCHEMBL18089697 0.78 ALDH1A1 (0.44) KDM4EKMT2ANOTUMTDP1MAPT
SCHEMBL2953687 0.78 CASP7 (0.44) KDM4EKMT2AGLAPOLBTDP1
SCHEMBL19124930 0.78 NOTUM (0.36) NOTUMTDP1CYP3A4ACHEALKBH5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250100993-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2025-03-27 US disclosed
EP-4469451-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF Inipharm, Inc. (US) 2024-12-04 EP disclosed
WO-2023146897-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2023-08-03 WO disclosed
WO-2023146897-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2023-08-03 WO disclosed
US-20170362508-A1 POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY DIC CORPORATION (JP) 2017-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250100993-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 KDM4E 3777/4885KMT2A 3549/4885GLA 2749/4885
US-20170362508-A1 POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY PBDC1, RCC1, PUF60 KDM4E 3572/4885KMT2A 3518/4885GLA 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.